Prostate Cancer Market
Prostate Cancer Market is segmented By Therapy Type (Hormone therapy, Chemotherapy, Immunotherapy, Radiation, Focal therapies, Cryosurgery, High-intensity focused ultrasound), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
What is the Size of the Prostate Cancer Market?
[44 market data tables, 43 figures, and 170 pages] Prostate cancer market size was valued at USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 9% during the forecast period (2022-2029). When the prostate gland begins to grow cells out of control, prostate cancer develops. The prostate gland is only found in men. The prostate gland produces some of the fluid found in sperm. Symptoms of prostate cancer are difficulties in Urination, but sometimes there are no symptoms. Some types of prostate cancer grow slowly. Prostate cancer is one of the most common types of cancer. New technologies in diagnostic testing are expected to boost the global prostate cancer market growth. The factors influencing the global prostate cancer market are the increasing research and development and the growing prevalence of prostate cancer.
Prostate cancer market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Prostate cancer market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American Prostate cancer market is expected to hold the largest share of the global market over the forecast period. Whereas the European Prostate cancer market is projected to continue its presence globally during the period of 2022- 2029.
Prostate Cancer Market Report Scope
Metrics |
Details |
Market CAGR |
9% |
Segments Covered |
By Therapeutics, By End User, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
To know more insights into the Market, Get Our Sample Brochure
Prostate Cancer Market Growth Drivers, and Dynamics
The increase in research and development in prostate cancer treatment is expected to drive the market growth
More information on the genetic changes that occur as prostate cancer develops and progresses is being discovered through research. Although early-stage prostate cancer contains fewer genetic changes than other types of cancer, researchers have discovered that as prostate cancer spreads throughout the body, it accumulates more mutations. Men with metastatic prostate cancer who have certain mutations may be eligible for "basket" clinical trials of novel medicines. Participants in such studies are chosen based on the mutations detected in their cancer rather than the location of cancer in the body.
A substantial percentage of men with advanced prostate cancer who participated in the NCI-MATCH trial exhibited mutations targeted with experimental medications. An immune checkpoint inhibitor is a medicine that inhibits proteins in immune cells, allowing the immune system to kill cancer cells more effectively. Pembrolizumab (Keytruda), a checkpoint inhibitor, has been approved to treat tumors with particular genetic characteristics, including prostate tumors. Pembrolizumab is also approved for any metastasized tumor with many genetic alterations. However, these characteristics are found in a small percentage of prostate tumors. Prostate cancer has mainly resisted treatment with checkpoint inhibitors and other immunotherapies, such as CAR T-cell therapy. Many NCI-funded researchers on the National Institutes of Health campus, as well as across the United States and the world, are attempting to find more effective strategies to combat prostate cancer. Some of this study is fundamental, looking into topics like cancer's biology basis and the social variables that influence cancer risk. Some are more clinical, attempting to transform fundamental data into better patient results.
However, Limitations associated with the treatment are expected to hamper the market growth. Treatments for prostate cancer can have a significant impact on a person's quality of life. Erectile dysfunction, the inability to develop and maintain an erection, incontinence, or the inability to control urine flow or bowel function are also possible side effects of these medications. Furthermore, many prostate tumors progress slowly and generate no signs of complications. As a result, many patients may think of postponing cancer therapy rather than commencing it immediately. It is referred to as "active surveillance." The malignancy is continuously evaluated for symptoms of worsening during active surveillance. Treatment will begin if the cancer is confirmed to be worsening.
What are the Segments Covered in the Prostate Cancer Market?
By Therapy Type: Hormone therapy, Chemotherapy, Immunotherapy, Radiation, Focal therapies, Cryosurgery, and High-intensity focused ultrasound
By End-User: Hospitals, Ambulatory Surgical Centers, and Specialty Clinics
The hormone therapy segment is projected to be the dominant segment in the market during the forecast period.
Prostate cancer hormone therapy is a medication that prevents the male hormone testosterone from being created or reaching cancer cells in the prostate. The majority of prostate cancer cells rely on testosterone to increase. Prostate cancer cells die or grow more slowly due to hormone therapy. Hormone therapy for prostate cancer may include drugs or testicular removal surgery. Androgen deprivation therapy is another name for hormone therapy for prostate cancer. Prostate cancers require androgens to grow early in their development. Hormone therapy, or treatments that lower androgen levels or block androgen activity, can slow the progression of prostate tumors that are castration sensitive, androgen-dependent, or androgen sensitive. Once they stop responding to hormone therapy, most prostate cancers become castration (or castrate) resistant. Even when androgen levels in the body are extremely low or undetectable, they continue to rise. These tumors were previously referred to as hormone-resistant, androgen-independent, or hormone-refractory; however, these words are no longer often used because the tumors' growth is not completely independent of androgens. Several novel hormone therapies are now available to treat cancers that have developed castration resistance. The most commonly used hormone therapies for prostate cancer and the first form of hormone therapy that most men with prostate cancer receive are treatments that suppress androgen production by the testicles.
Which region is dominating the global Prostate Cancer Market?
North America is the dominating region during the forecast period.
The growing prevalence of prostate cancer and increasing research and development is expected to drive the market growth in this region. Prostate cancer strikes roughly one out of every eight men at some point in their lives. Prostate cancer is more common in older men and non-Hispanic Black men. Men over 65 account for around 6 out of every 10 cases, whereas men under 40 are extremely uncommon. According to the American Cancer Society, approximately 268,490 new cases of prostate cancer will be diagnosed in the United States in 2022. Prostate cancer claims the lives of approximately 34,500 men each year. More than 3.1 million men in the United States are diagnosed with prostate cancer. Hence, the increasing prevalence of prostate cancer is expected to boost market growth in this region.
Competitive Landscape:
The global prostate cancer market is highly competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Johnson & Johnson, Astella, Inc., Sanofi Aventis, IPSEN, Bayer AG, AstraZeneca, Valent Pharmaceuticals LLC, Novartis International AG, Clovis Oncology Inc., and others. On March 23rd, 2022, Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) was approved by the Food and Drug Administration for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. May 2021, Astellas Pharma Inc. announced that the European Commission (EC) had approved an additional indication for the oral once-daily therapy XTANDI for adult men with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer or mCSPC). With this indication, enzalutamide is now the only oral treatment approved by the EC to treat three distinct types of advanced prostate cancer such as non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mHSPC. In September 2021, Johnson & Johnson's Prostate Cancer Drug Erleada Won National Institute of Health and Care Excellence Approval.
COVID-19 Impact:
Negative impact on the global market.
The COVID-19 epidemic has negatively influenced early diagnosis by lowering participation in screening programs and time from diagnosis to surgery/radiotherapy, which may translate into poorer prostate cancer-specific mortality in the coming years. Patients with metastatic prostate cancer history of symptomatic COVID-19 may also experience more severe chemotherapy-related side effects. Hence, covid-19 is expected to have a negative impact on the global market for prostate cancer.